September 15-17, 2025
Delivered as a Hybrid EventFairmont Chicago Millennium Park, Chicago, ILKey Sessions
Reserved for Keynote – To Be Announced!
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day Two - CT (Central Time)
keyboard_arrow_leftSearch & Filter
close
Streams
Formats
Day Two - CT (Central Time)
close
Streams
Formats
Showing 1 of 1 Streams
Showing 1 of 1 Streams
Track C: The IRA Rollercoaster: Thrills, Chills & Strategic Skills
2:25pm - 3:05pm
Part B Drugs and IRA: Navigating the Unique Challenges of Physician-Administered Products
- Understand the specific considerations for physician-administered drugs entering Medicare negotiation in Round 3, including ASP reporting requirements and distinct operational challenges
- Assess the potential marketplace impacts of MFP on Part B drug reimbursement, formulary positioning, and future investment decisions for injectable and infused therapies
- Explore strategies for communicating with providers and health systems about Part B drug pricing changes and their potential effects on acquisition costs and administration fees
- Examine policy considerations and potential regulatory changes that may affect Part B drug pricing and reimbursement as IRA implementation evolves
- Natalie Morris - Director, Public Policy & Reimbursement, Takeda
- Kathleen Peterson - Counsel, Hogan Lovells US LLP
- Samantha Marshall - Counsel, Hogan Lovells
Showing 2 of 2 Streams
Track B: State Level Policy Trends & Updates: The United States of Complexity
Track C: The IRA Rollercoaster: Thrills, Chills & Strategic Skills
4:20pm - 5:00pm
State Drug Pricing Disclosure: Balancing Compliance and Trade Secret Protection
- Navigate evolving state transparency requirements while effectively safeguarding sensitive pricing information through proven trade secret protection strategies
- Understand current enforcement priorities and respond strategically to state inquiries based on recent case studies from Oregon, New York, and Colorado
- Develop cross-functional protocols to streamline reporting processes while maintaining consistency across multiple state submissions
- Implement practical approaches to engage constructively with state regulators while advocating for reasonable interpretations of disclosure requirements
- Judd Caulfield - Senior Counsel, Takeda Pharmaceuticals
- Sara Simon, JD - Counsel, Porzio, Bromberg and Newman
3:35pm - 3:40pm
Inflation Rebates First Year Implementation Insights and Strategic Considerations
- Review practical experiences from the first invoicing cycles for inflation rebates, including calculation methodologies, dispute resolution processes, and system integration challenges
- Develop effective approaches for evaluating inflation rebate invoices and managing the compressed timeframe for appeals and adjustments
- Inspect the complex interplay between price increase decisions, inflation rebates, and other pricing considerations in today's regulatory environment
- Explore innovative strategies for maintaining product lifecycle value while navigating the constraints of inflation penalties across Medicare and commercial markets
- Establish cross-functional workflows connecting government pricing, finance, and treasury functions to manage the evolving payment requirements across inflation rebates and MFP implementation
- Design system integration approaches that ensure accurate calculation, timely payment, and proper financial reporting in the new regulatory landscape
- Roneil Narciso - Director - Strategic Pricing & Contracting, AVEO Oncology
- Melody Hamel - Senior Operations Counsel, Viatris Inc
- Jessica Catalano - Senior Director, Government Pricing & Compliance, Teva
- Susan Dunne - Managing Director, Riparian
Filter
Streams
Formats
Choose Day